Relay Therapeutics, Inc. Stock Price, News & Analysis

Relay Therapeutics has announced key developments regarding RLY-4008, following a productive end-of-phase 1 meeting with the FDA. The company plans a single-arm trial for FGFR2-fusion cholangiocarcinoma, potentially facilitating accelerated approval. Interim data revealed a 62% confirmed partial response rate among FGFRi-naïve patients treated with a 70 mg dose. Additionally, Relay introduced three new programs targeting HR+/HER2- breast cancer and confirmed adequate funding to sustain operations through 2025.

Relay Therapeutics, a clinical-stage precision medicine company, has announced that registration is now open for its virtual analyst and investor event scheduled for June 27, 2022. The event will run from 8:00 a.m. to 9:00 a.m. ET and will be accessible via the company’s website. Relay Therapeutics aims to innovate drug discovery through its advanced Dynamo™ platform, targeting oncology and genetic diseases. The company focuses on developing transformative therapies utilizing unique computational and experimental technologies.

Relay Therapeutics (Nasdaq: RLAY) will participate in two upcoming fireside chats: the Cowen 3rd Annual Oncology Innovation Summit on June 2, 2022, at 11:30 a.m. ET and the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 5:40 p.m. ET. Both events will be webcast live, accessible via Relay Therapeutics' website, and archived for 30 days post-event. The company focuses on precision medicines, integrating advanced computational and experimental technologies to enhance drug discovery in oncology and genetic disease.

Relay Therapeutics (Nasdaq: RLAY) reported its first quarter 2022 financial results, showing a net loss of $62.0 million or $0.57 per share, up from a net loss of $42.2 million in Q1 2021. As of March 31, 2022, the company held approximately $898 million in cash and equivalents, sufficient to support operations into 2025. Notable achievements include the initiation of the combination arm for RLY-2608 and continued enrollment for RLY-4008 expansion cohorts. The company anticipates releasing initial clinical data for RLY-2608 in H1 2023.

Relay Therapeutics (Nasdaq: RLAY) announced participation in a fireside chat at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 3:20 p.m. PT in Las Vegas, NV. The chat will be broadcast live via their website and can be accessed under the Events section. An archived replay will be available for 30 days post-event. Relay Therapeutics focuses on precision medicines, leveraging its Dynamo™ platform for drug discovery in oncology and genetic diseases.

Relay Therapeutics (Nasdaq: RLAY) will announce its first quarter 2022 financial results and corporate highlights on May 5, 2022, after market close. The company is focused on transforming drug discovery through its innovative Dynamo™ platform, which leverages advanced computational and experimental technologies to target previously difficult-to-drug proteins. Relay Therapeutics aims to pioneer new small molecule therapies primarily for oncology and genetic diseases, potentially impacting patient outcomes significantly.

Relay Therapeutics (Nasdaq: RLAY) announced promising interim clinical data for RLY-4008, the first therapy targeting FGFR2, showing approximately 80% of patients with FGFR2-altered tumors achieved tumor size reductions. The company reported a net loss of $67.5 million for Q4 2021, with total cash and investments of $958.1 million as of December 31, 2021, expected to fund operations into at least 2025. Relay also presented preclinical data for RLY-2608, an innovative PI3Kα inhibitor, and outlined significant growth in R&D expenses due to increased clinical activities.

Relay Therapeutics (Nasdaq: RLAY) announced plans to release its fourth quarter and full year 2021 financial results on February 24, 2022, after market close. The company specializes in precision medicine, leveraging advanced computational and experimental technologies to enhance drug discovery. Notably, Relay Therapeutics utilizes its Dynamo™ platform to target challenging protein structures, focusing on therapies for oncology and genetic diseases. A teleconference will not be held alongside this press release.

Relay Therapeutics (Nasdaq: RLAY) will participate in two upcoming healthcare conferences. The first is a fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference on February 9, 2022, at 9:30 a.m. ET. Following this, Relay will join a panel discussion at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 12:50 p.m. ET. Both events will be webcast live, and viewers can access them via the Investors & Media page on Relay's website. Archived replays will be available for 30 days post-event.